Literature DB >> 18716880

The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients.

Tamas Szamosi1, Peter Laszlo Lakatos, Aniko Szilvasi, Laszlo Lakatos, Agota Kovacs, Tamas Molnar, Istvan Altorjay, Maria Papp, Orsolya Szabo, Anna Satori, Zsolt Tulassay, Pal Miheller, Henrik Csaba Horvath, Janos Papp, Attila Tordai, Hajnalka Andrikovics.   

Abstract

PURPOSE: In previous studies the NFKBIA 3'UTR (untranslated region) AA genotype was associated with Crohn's disease (CD), while the NFKB1-94ins/delATTG mutation increased the risk for ulcerative colitis (UC). The aim of our study was to investigate these two polymorphisms and patients' response to medical therapy and/or disease phenotype in Hungarian inflammatory bowel disease (IBD) patients.
METHODS: NFKBIA 3'UTR- and NFKB1-94ins/delATTG polymorphisms were investigated in 415 unrelated IBD patients (CD: 266 patients, mean age 35.2 +/- 12.1 years, duration 8.7 +/- 7.5 years; UC patients: 149, mean age 44.4 +/- 15.4 years, duration 10.7 +/- 8.9 years) and 149 controls by PCR-restriction fragment length polymorphism (RFLP) analysis. Detailed clinical phenotypes were determined by reviewing the medical charts.
RESULTS: The NFKBIA 3'UTR and NFKB1-94ins/delATTG genotypes and allele frequencies were not significantly different among IBD and controls. In patients with UC, the 3'UTR GG genotype was associated with extensive colitis (55.3 vs. 29.4%, odds ratio 2.97, 95% confidence interval 1.45-6.08). The presence of variant alleles did not predict response to steroids, infliximab, or need for surgery.
CONCLUSIONS: The NFKBIA 3'UTR GG genotype was associated with an increased risk for extensive colitis in Hungarian patients. In contrast, variant alleles did not predict response to medical therapy or need for surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716880     DOI: 10.1007/s10620-008-0351-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

2.  No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort.

Authors:  M M Mirza; S A Fisher; C Onnie; C M Lewis; C G Mathew; J Sanderson; A Forbes
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

4.  Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Authors:  Tibor Hlavaty; Marc Ferrante; Liesbet Henckaerts; Marie Pierik; Paul Rutgeerts; Severine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

5.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 6.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

Authors:  Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease.

Authors:  K Thiele; A Bierhaus; F Autschbach; M Hofmann; W Stremmel; H Thiele; R Ziegler; P P Nawroth
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

8.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

9.  Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; N F Krynetskaia; Y Yanishevski; W E Evans
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

10.  ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.

Authors:  Simon Fischer; Peter Laszlo Lakatos; Laszlo Lakatos; Agota Kovacs; Tamas Molnar; Istvan Altorjay; Maria Papp; Aniko Szilvasi; Zsolt Tulassay; Janos Osztovits; Janos Papp; Pal Demeter; Richard Schwab; Attila Tordai; Hajnalka Andrikovics
Journal:  Scand J Gastroenterol       Date:  2007-06       Impact factor: 2.423

View more
  6 in total

Review 1.  Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease.

Authors:  Laszlo Bene; Andras Falus; Noemi Baffy; Andras Kristof Fulop
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

2.  Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis.

Authors:  Meilan Liang; Xinyu Xu; Yaoyao Gong; Yurong Tang; Lin Lin
Journal:  Dig Dis Sci       Date:  2012-07-25       Impact factor: 3.199

3.  Co-stimulatory CD28 and transcription factor NFKB1 gene variants affect idiopathic recurrent miscarriages.

Authors:  Maneesh Kumar Misra; Bharti Singh; Aditi Mishra; Suraksha Agrawal
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

4.  Association of the NFKBIA gene polymorphisms with susceptibility to autoimmune and inflammatory diseases: a meta-analysis.

Authors:  Guo-Long Zhang; Yan-Feng Zou; Xiao-Liang Feng; He-Jian Shi; Xu-Feng Du; Min-Hua Shao; Yong Gu; Qing Zhou
Journal:  Inflamm Res       Date:  2010-05-21       Impact factor: 4.575

5.  Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα.

Authors:  Xiao Feng; Hao Wang; Shicai Ye; Jiaxi Guan; Wenkai Tan; Si Cheng; Guoli Wei; Weiyun Wu; Feng Wu; Yu Zhou
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

6.  Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.

Authors:  Steffen Bank; Paal Skytt Andersen; Johan Burisch; Natalia Pedersen; Stine Roug; Julie Galsgaard; Stine Ydegaard Turino; Jacob Broder Brodersen; Shaista Rashid; Britt Kaiser Rasmussen; Sara Avlund; Thomas Bastholm Olesen; Hans Jürgen Hoffmann; Marianne Kragh Thomsen; Vibeke Ostergaard Thomsen; Morten Frydenberg; Bjørn Andersen Nexø; Jacob Sode; Ulla Vogel; Vibeke Andersen
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.